PRRT2 and cancer: To assess how cancer-associated mutations affected PKCθ activity, we monitored PKC activity in cells using the genetically-encoded fluorescence resonance energy transfer (FRET)-based reporter for PKC activity, C kinase activity reporter 2 (CKAR2) [62,63]; we also took advantage of the PKCθ-specific inhibitor, compound 20 (C20), to selectively inhibit PKCθ over the other PKC isozymes [64].